Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Piers Whitehead joins Neovacs

This article was originally published in Scrip

Executive Summary

Neovacs, a French biotechnology company developing proprietary immunotherapeutics for autoimmune and chronic diseases, has named Piers Whitehead vice-president of corporate development. He has more than 15 years' experience in the life sciences industry, having previously served as vice-president of business and corporate development for VaxGen. Before that, he was a vice-president at Mercer Management Consulting, where he headed the firm's San Francisco office.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC004291

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel